Medgenics(Regs) Share Discussion Threads

[sicilian_kan] 16/4/2010 08:01

I'm not sure many knew of the RNS as it was released mid morning. I think the company could issue more RNS's at 7am like everyone else. I agree, it should have risen on this, but I do not know of a bio so undervalued as this one and am treating it as a buying opportunity (MEDU shares in particular are cheap at the moment).

I would envisage the next key movement being contract news this year for (a) Infradure (b) the obesity side and (c) possibly Epodure. Last time we got contract news, on the hemophilia side (at a preclinical stage a year earlier than Infradure is now), the deal was worth $7m to get to clinical trial readiness with a deal option there after. Infradure should attract something like $10m - $20m upfront on a deal with $500m milestones and 20% royalties thereafter. Epodure could get $20m - $30m up front. Obesity deal likely to be around $5m up front to get to clinical trials.

If any of these deals are signed, the share price will go far beyond the 12p hit by the $7m preclinical hemophilia deal. I think the deals could be signed this year and have a long term holding mentality here.

[andrbea] 16/4/2010 07:51

price didn't budge yesterday

disappointing..

[sicilian_kan] 16/4/2010 07:50

And the new scientific advisor to Medgenics is the Professor Bruce R. Bacon, referred to in the RNS. You can't get much better authority than him and he has previously been the president of the American Association for the Study of Liver Diseases (good connections here too for Medgenics). He said "The
development of this novel Biopump technology provides the potential for an
improved method for safe, effective interferon delivery that is cost-effective
and efficacious."

[sicilian_kan] 16/4/2010 07:48

The above news is first class. What it shows is that INFRADURE is matching EPODURE in its preclinical trials, and therefore (1) INFRADURE could well have the same clinical trial results as EPODURE (i.e. v successful) and (2) The Biopump technology is one which looks like it can replicate itself easily across a whole range of proteins (note the protein therapy market is estimated to be worth $87bn this year!). This means that the hemophilia deal could also have good preclinical results, resulting in the extra $4m and the contract deals. Finally, note the comment that Medgenics hopes to bring INFRADURE to clinical trials in the near future. I would envisage that to mean this year, which has always been their plan.

1. INFRADURE Biopumps provide sustained IFNa production at or exceeding 1-2 µg/day for at least 129 days in vitro. The Biopumps produced from the skin of 7 patients, tested in vitro, all met the target potency criteria

2. Data shows that Biopumps manufactured from skin samples of the same patient can produce different proteins: EPO and IFNa. This demonstrates the
concept that the Biopump is a platform technology that has the potential for
administration of a wide range of therapeutic proteins.

3. These findings parallel those found with EPODURE Biopumps tested under similar circumstances in vitro and in SCID mice. Based on the data reported at the EASL 2010 conference, Medgenics believes sustained IFNa treatment for chronic hepatitis C should be achievable by administering INFRADURE Biopumps to typical hepatitis C patients, in like manner to the results reported for EPODURE in treatment of anemia. Medgenics hopes to bring INFRADURE to clinical trials in the near future. Medgenics has produced more than 5000 Biopumps, all of which have shown the capability for the sustained production of therapeutic proteins such as erythropoietin (EPO), IFNa, and others.

Finally, it is worth noting that the current treatment involves administration of injections weekly for 6 to 12 months (for IFNa).

[sicilian_kan] 15/4/2010 23:21

Medgenics Showcase at Major European Liver Meeting

TIDMMEDG

RNS Number : 2328K
Medgenics Inc
15 April 2010

For release: 15 April 2010

SUSTAINED INTERFERON ALFA-2b (IFNa) PRODUCTION IN VITRO AND DELIVERY IN VIVO BY
MEDGENICS DERMAL MICROORGAN BIOPUMPS SHOWCASED AT THE MAJOR EUROPEAN LIVER
MEETING IN VIENNA

Interferons have been shown to be effective treatment for chronic hepatitis C
but their use has been associated with frequent side effects. Current treatment involves administration of peginterferon alpha injections weekly for 6 to 12 months. These injections generate high peak levels of interferon alpha (IFNa), which give rise to side effects, cause patient discomfort and lead some patients to discontinue treatment. The provision of consistent therapeutic levels of IFNa over a prolonged period of time could substantially reduce the side effect profile and improve the treatment of chronic hepatitis C, a disease that affects approximately 170 million people around the world.

Medgenics, Inc. has a unique platform technology that creates dermis-based micro-organs, called Biopumps, capable of producing therapeutic proteins. A needle biopsy taken from a patient's own skin is used to prepare the Biopump. Medgenics has produced more than 5000 Biopumps, all of which have shown the capability for the sustained production of therapeutic proteins such as erythropoietin (EPO), IFNa, and others. In previous clinical studies, the
Company has reported that a single administration of a few Biopumps producing
the protein EPO has provided effective sustained treatment of anemia for more
than a year. Patients with chronic kidney disease have been treated for periods of 6 to 16 months, without the need for additional EPO injections.

On April 15th at the 2010 European Association for the Study of Liver Diseases
(EASL) conference, Medgenics is presenting findings from key preclinical studies of Biopumps that produce IFNa intended for use in the treatment of chronic hepatitis C. In the two posters being presented, Medgenics reports (1) the reliable sustained production by Biopumps of potent human IFNain vitro, and (2) the in vivo production and delivery of human IFNa in SCID mice following the implantation of such Biopumps, called INFRADURE. In anticipated clinical use, as with the anemia clinical trial, each patient would receive the requisite number of INFRADURE Biopumps intended to provide their recommended daily IFNa dose. Dose levels can be increased by administering additional Biopumps, or reduced at any time by ablating one or more of Biopumps already administered.

Key points arising from these posters are:

To be commercially viable, IFNa Biopumps should each produce a target of > 1
µg/day of IFNa in vitro. The data presented in these posters showed that
INFRADURE Biopumps provide sustained IFNa production at or exceeding 1-2 µg/day
for at least 129 days in vitro.

INFRADURE Biopumps produced from the skin of 7 patients, tested in vitro, all
met the target potency criteria, despite moderate variability in the levels
reached between patients' skin samples.

Data are presented that show Biopumps manufactured from skin samples of the same patient producing different proteins: EPO and IFNa. This demonstrates the
concept that the Biopump is a platform technology that has the potential for
administration of a wide range of therapeutic proteins.

Dose-dependent delivery and non-toxicity were demonstrated by in vivo studies in mice using INFRADURE Biopumps producing an IFNa dose appropriate for 70 kg
humans. Two doses were administered: (1.3 µg/day and 4,0 µg/day, the "lower"
and "higher" doses respectively were implanted into 20 g SCID mice.

Dose response was seen on day 10 post-implantation: the "lower" group averaged
1700 pg/ml, and the "higher" group averaged 8,900 pg/ml. During the 3-4 months thereafter, the initially high levels of IFNa in mice were reduced to normal therapeutic levels in the10 pg/ml range. Serum levels of the "higher" dose animals were always greater than those of "lower" dose animals, and were well tolerated even though both doses greatly exceeded those that are used
clinically. Necropsy revealed no abnormalities, indicating that even these
large doses of IFNa from INFRADURE Biopumps were well tolerated.

These findings parallel those found with EPODURE Biopumps tested under similar
circumstances in vitro and in SCID mice.

Based on the data reported at the EASL 2010 conference, Medgenics believes
sustained IFNa treatment for chronic hepatitis C should be achievable by
administering INFRADURE Biopumps to typical hepatitis C patients, in like manner to the results reported for EPODURE in treatment of anemia. Medgenics hopes to bring INFRADURE to clinical trials in the near future.

Medgenics believes Biopumps will provide a potentially improved approach to
therapy with fewer side effects and is likely to provide a more cost-effective
treatment for hepatitis C and other chronic diseases. Biopumps represent an
example of personalized medicine as the treatment is unique to the patient.

Commenting on the data being presented, Professor Bruce R. Bacon, past president of the American Association for the Study of Liver Diseases said "The
development of this novel Biopump technology provides the potential for an
improved method for safe, effective interferon delivery that is cost-effective
and efficacious."

If you would like a copy of the posters and comparative data for EPODURE, please contact: Anna Dunphy ([e-mail]) or Mike Wort ([e-mail]).

[smellyjim] 14/4/2010 16:38

lol, well you won't show your face on the TMC through embarrasment so I've had to route you out via your kennels. It was this dog that barked the loudest of your pack!

[sicilian_kan] 14/4/2010 16:34

sj, good to see you taking a lasting interest here.

[smellyjim] 14/4/2010 16:31

Kan only me and you here it seems and as you know I wouldn't touch this with a bargepole! Awful chart as well, that makes you holding the baby. Good luck, one suspects you'll more than need it.

[sicilian_kan] 14/4/2010 07:30

14 April 2010
Medgenics, Inc

('Medgenics' or the 'Company')

Change of Name of Nominated Adviser

The Company announces that Blomfield Corporate Finance Limited, the Company's Nominated Adviser has changed its name to Religare Capital Markets (UK) Limited - trading as Religare Capital Markets.

For further information:

Andrew Pearlman [phone]
CEO

Medgenics, Inc

James Pinner / Derek Crowhurst [phone]
Religare Capital Markets
www.religarecm.com

[sicilian_kan] 12/4/2010 07:49

Final results came out in May last year.

[sicilian_kan] 06/4/2010 22:29

The EASL conference is on Wednesday next week. There could be a few more tick ups before.

[sicilian_kan] 06/4/2010 17:10

Yep, nice to see the tick up. And welcome to the thread.

Interesting as well is to see the price of MEDU shares compared to MEDG shares. I bought a £2k MEDU top up the other day at 4.6p (sub the 5p small placing).

Today, doing a dummy sell, I was offered 5.8p to sell MEDG shares (i.e. significantly more than the MEDU purchase price). Yet the MEDU shares are arguably the better ones to have.

In short, I could switch my whole holding over from MEDG to MEDU and get more shares / bank profit for free.

[mike111d] 06/4/2010 16:16

A blue start to the new tax year.

[sicilian_kan] 31/3/2010 14:18

Thanks dp. It won't take much for this to rocket.

[dawsonpaul] 31/3/2010 14:08

keep up the good work SK. I only have a grand in here.

[sicilian_kan] 31/3/2010 07:25

Great opportunity that, with 7,000 liver specialist delegates there.

[sicilian_kan] 31/3/2010 07:23

RNS out yesterday, that I have just noticed:

RNS Number : 4042J
Medgenics Inc
30 March 2010

For release: 30 March 2010

MEDGENICS PRESENTS FIRST DATA ON INTERFERON PRODUCING BIOPUMPS AT THE 2010 EASL CONFERENCE IN VIENNA

During the 2010 EASL conference on liver disease in Vienna, Austria, which takes place between April 14 and April 18, 2010, Medgenics, Inc ("Medgenics" or the "Company") will be presenting two posters providing data on their INFRADURE
Biopumps that use a patient's own tissue to produce and deliver interferon-alpha (IFNa) in therapeutic amounts consistently and over a sustained period, the first time thesedata have been presented at a clinical conference. This prestigious European annual conference for liver disease is attended by more than 7,000 delegates, representing the key opinion leaders in treating liver disease.

The INFRADURE technology is being developed for use in treating Hepatitis-C, by
providing up to 6 months sustained IFNa treatment from a single administration,
using the patient's excised dermis sample taken by needle biopsy and converted
into a "Biopump" producing IFNa. Based on prior experience reported using the
same Biopump approach to achieve sustained production of a different protein,
erythropoietin, the Company believes these INFRADURE Biopumps will produce a
consistent level of IFNa over a prolonged period. In this way, the Company
plans to provide the benefits of interferon therapy without the well known toxic effects caused by the way interferon is administered today; i.e., a weekly
series of at least 24 injections. Patients treated with today's IFNa injections usually suffer major flulike symptoms largely due to the high dose of the bolus injection, and many prefer to forego treatment because of the toxic effects. By providing a steady level at the requisite dose, Medgenics believes patients will receive effective and much more tolerable therapy for Hepatitis-C.

INFRADURE Biopumps are made from microorgans - half-toothpick sized slivers of
excised dermis, the lower layer of skin - which are processed outside the body
for 10 days causing their cells to produce IFNa. After a week measuring each
Biopump's IFNa production, the requisite dosage of IFNa is given by inserting
the requisite number of Biopump units subcutaneously - current data suggest that 1-3 Biopump units should be adequate to provide the interferon therapy used for a typical patient with Hepatitis-C.

Proof of principle of this new approach to protein production and delivery has
been established through the generation of more than 5,000 Biopumps producing a
range of different therapeutic proteins in the laboratory. The most advanced
programme is EPODURE Biopumps which produce erythropoietin for anaemic patients
with chronic kidney disease. In its ongoing Phase I-II study in 2009 Medgenics
reported that haemoglobin levels were elevated and sustained for 6-12 months
from a single administration of low dose EPODURE Biopumps.

The study presented in these two posters provides data which showthat long term
IFNa production and delivery can be achieved in SCID mice, and long-term IFNa
production can be maintained in vitro.

Commenting on the posters being presented, Medgenics' Chairman of the Board Dr.
Eugene Bauer said, "We have been encouraged by the clinical data that have been
generated with EPODURE Biopumps and it is gratifying that the higher dose trials are scheduled to commence in the near term. The data presented at this
conference demonstrate how we can successfully produce Biopumps for other
important therapeutic proteins, including IFNa. We believe the INFRADURE
Biopump could offer great hope for a significant improvement in the treatment of Hepatitis-C."

For further comment from Dr. Andy Pearlman, CEO of Medgenics, and to order a
copy of the posters following publication, please contact Anna Dunphy
([e-mail]) or Mike Wort ([e-mail]) and we would be
delighted to arrange for that.

[sicilian_kan] 31/3/2010 07:20

An article discussing the hemophilia deal:



Medgenics: USD 7 million deal validates Biopump protein platform
October 25th, 2009

One week ahead of BIO-Europe 2009, Medgenics announced its first preclinical development and option agreement with what it described as "a major international biopharmaceutical company that is a market leader in the field of hemophilia."

Constrained from naming his partner, CEO Andrew Pearlman told partneringNEWS™ that "Company X jumped the queue for our development projects to sign a first stage standstill deal to prove the feasibility for Biopump to produce and deliver clotting protein Factor VIII for the sustained treatment of hemophilia."

"Medgenics will receive USD 4 million during the year for standstill and development. Once our partner is convinced by the results we will receive an additional USD 3 million, including a period of exclusivity to negotiate a definitive commercialization agreement," he revealed.

"What is significant in the agreement", Pearlman highlighted "is that the pharmaceutical company is pursuing our disruptive technology. That is a significant vote of confidence for our unique technology, but also encouraging for other potential partners who are considering our approach."

"Given that we are only commencing our program to develop a Biopump to produce Factor VIII," Pearlman added, "the fact that a market leader in hemophilia has entered into this type of agreement clearly shows that the potential of the platform was obvious even at this early stage. It testifies to the promise of the Biopump technology for use in treating hemophilia, and further validates the belief that our platform can be applied to help treat many chronic diseases and will attract further interest from other major partners."

[smellyjim] 25/3/2010 09:12

17% spread, in dire need of cash from what I can make out and the sole member of this board on another board desperately trying to ramp this pile of garbage!!

Avoid this one at all costs I say, another ERX job here.

[sicilian_kan] 17/3/2010 15:11

I hardly call 67 posts on the whole board in 4.5 months ramping, a few of which are yours.

[smellyjim] 17/3/2010 14:57

no trades today = no interest , no wonder kan is playing the desperate ramper!

[smellyjim] 17/3/2010 14:53

you know fine well you're trapped in this piece of muck kan hence you're trying to talk it up on other threads!! So what they going to raise much needed cash at here, 2p or 3p?! Least it will bring down your average if you can get in on the placing! Keeps th edream afloat for a bit longer. Newbies though should forget this one, perenial fundraiser!

[sicilian_kan] 17/3/2010 07:56

smellyjim, if you knew about shorting, you would know that you cannot short companies of this size.

The chart is very good for those who bought in at around 3p. The leg up to 11p was based on a contract for their third product and there are negotiations for far more valuable products higher up their pipeline that are ongoing. The share price if these were licensed out would be far higher than 11p.

Can I suggest that you actually try analysing the best in class trial results or the multi million dollar contract signed with a market leader for MEDG's product, or a world liver expert joining the company. Your posts might be a bit better then and you only seem to be here because I post on TMC.

[smellyjim] 17/3/2010 07:37

you're on your own here Kan and no wonder looking at the chart! Looks like you're trapped here given they'll need to raise more soon to keep afloat. Wouldn't touch these with a bargepole but i'll hang around until the lights go out ;-))
What else you in so i can use some spare change in my Ig index shorting account??!!

[sicilian_kan] 12/3/2010 08:37

In the placing there is a new company that took stock on, called "UK Private Healthcare Limited". Anyone know anything about them?